SARC037 is Open and Accruing

A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients: NCT04067115

In SARC037 we are enrolling patients with refractory or relapsed Ewing sarcoma that has the EWS-FLI1 fusion type for which there is no known therapy proving to prolong survival. Eligible patients must have measurable disease, ECOG Performance Status of 0-2 or Lansky of 50, and adequate organ function.  The trial includes several important and exciting correlative studies to help us better understand the biology of Ewing as well as the impact of dose and schedule of the study treatment.

It is currently open at Children’s Hospital of Philadelphia, Children’s Hospital of Los Angeles, the National Cancer Institute, University of Michigan, Dana-Farber Cancer Institute, and the University of Pennsylvania. We have funding mechanisms to help with travel.

In a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this.  If you want to learn more about this study or have any questions, please contact Patrick Grohar, MD, PhD (GroharP@CHOP.edu).

See more about SARC037.

We appreciate your support and help!